Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer’s Disease At 18-Months

Great Lakes Clinical Trials is pleased to share this press release in regards to a Alzheimer's disease research program in which we are participating.  If you are interested in learning how to participate, please click HERE for more information.

FOR IMMEDIATE RELEASE
June 5, 2018
Eisai Co., Ltd. (www.eisai.com)
Biogen Inc. (www.biogen.com)

Results Of The Phase II Study Demonstrated A Statistically Significant Difference In Amyloid Beta In Brain

 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (Aβ) levels in the brain measured by amyloid-PET (positron emission tomography). A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant. This study, a Phase II study of 70 patients, is the first study of a BACE inhibitor to show a statistically significant difference in amyloid beta in the brain while also suggesting a delay of clinical symptom decline in exploratory endpoints. 

To download a full version of the press release, click HERE.
You can also view it directly on Biogen's website by clicking HERE or on Eisai's website by clicking HERE

shutterstock_115798375.jpg